Beispiel: Heart Attack

Klinische Studien zur Neisseriaceae-Infektionen

Insgesamt 507 ergebnisse

NCT00091728

Beendet

Hormonal Contraception and Risk of Chlamydia and Gonorrhea

Bedingungen: Chlamydia Infection; Neisseriaceae Infection
NCT04502693

Rekrutierung

Study to Assess Effectiveness of GlaxoSmithKline's (GSK's) Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults.

Bedingungen: Infections, Meningococcal
NCT04318548

Rekrutierung

Study to Assess the Immunogenicity and Safety of GSK's Meningococcal Group B Vaccine When Administered Concomitantly With GSK's Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age

Bedingungen: Infections, Meningococcal
NCT04184336

Rekrutierung

Enhanced Population-based Core Surveillance of Meningococcal Invasive Infections at Participating Centers Across Canada

Bedingungen: Invasive Meningococcal Disease
NCT03652610

Abgeschlossen

A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adults 18 to 40 Years of Age

Bedingungen: Infections, Meningococcal
NCT03621670

Rekrutierung

GlaxoSmithKline's (GSK) Safety and Immunogenicity Study of GSK Meningococcal Group B and 13-valent Pneumococcal Vaccines Administered Together With Routine Infant Vaccines in Healthy Infants

Bedingungen: Infections, Meningococcal
NCT04239430

Noch nicht rekrutiert

Propositive (Protecting Positive People From Meningococcal Infection) Follow-up Study

Bedingungen: HIV/AIDS; Meningococcal Disease
NCT02986854

Abgeschlossen

Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination

Bedingungen: Infections, Meningococcal
NCT02946385

Abgeschlossen

Study to Assess the Immunological Long-term Persistence of Antibodies (Abs) 2 Years After GlaxoSmithKline (GSK) Meningococcal ABCWY Vaccination in the V102_15 (NCT02212457) and Response to a Booster in Adolescents

Bedingungen: Infections, Meningococcal
NCT02640677

Abgeschlossen

Safety of 4CMenB Exposure During Pregnancy

Bedingungen: Infections, Meningococcal
NCT02639351

Abgeschlossen

Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine

Bedingungen: Infections, Meningococcal
NCT02446743

Abgeschlossen

Combined Study - Phase 3b MenB Long Term Persistence in Adolescents

Bedingungen: Infections, Meningococcal
NCT02446691

Abgeschlossen

Evaluation of Antibody Persistence Following 4 MenACWY Vaccinations

Bedingungen: Infections, Meningococcal
NCT02212457

Abgeschlossen

Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents

Bedingungen: Infections, Meningococcal
NCT02106390

Abgeschlossen

Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants

Bedingungen: Infections, Meningococcal
NCT02451514

Abgeschlossen

A Study to Evaluate 4-year Antibody Persistence and Booster Response Following MenABCWY Vaccination in Healthy Adolescents and Young Adults Who Previously Participated in Studies V102_02 (NCT01210885) and V102_02E1 (NCT01367158)

Bedingungen: Meningococcal Disease; Infections, Meningococcal
NCT01962207

Abgeschlossen

The Long-term Antibody Persistence of MenACWY-TT Vaccine (PF-06866681) Versus Meningitec(Registered) or Mencevax(Registered) ACWY in Healthy Adolescents and Adults and a Booster Dose of MenACWY-TT Administered 10 Years Post Primary Vaccination

Bedingungen: Infections, Meningococcal
NCT01939158

Abgeschlossen

Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™Vaccine

Bedingungen: Infections, Meningococcal
NCT01934140

Abgeschlossen

Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primary Vaccination

Bedingungen: Infections, Meningococcal
NCT01900899

Abgeschlossen

Persistence of Antibodies After Meningococcal Vaccine PF-06866681 in Healthy Children

Bedingungen: Infections, Meningococcal
NCT02287688

Abgeschlossen

Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Infant Study

Bedingungen: Meningococcal Disease; Infections, Meningococcal
NCT01755689

Abgeschlossen

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults

Bedingungen: Infections, Meningococcal
NCT01808365

Abgeschlossen

N. Meningitidis Carriage Study

Bedingungen: Infections, Meningococcal
NCT01777308

Abgeschlossen

Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination

Bedingungen: Infections, Meningococcal
NCT01767376

Abgeschlossen

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Subjects Between 11 and 25 Years of Age

Bedingungen: Infections, Meningococcal